Navigation Links
S1 Biopharma Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
Date:6/5/2015

NEW YORK, June 5, 2015 /PRNewswire/ -- Yesterday's FDA Advisory Committee recommendation for the approval of flibanserin was a landmark step for women's health, addressing the important unmet medical need for women living with hypoactive sexual desire disorder, or HSDD.  We are especially pleased for S1 Biopharma's Dr. Robert Pyke who fathered flibanserin at Boehringer Ingelheim before it was acquired by Sprout Pharmaceuticals.  Dr. Pyke joined S1 Biopharma as Chief Medical Officer in 2012 to develop our next-generation drug for HSDD, Lorexys.

HSDD is a medical condition marked by a lack of sexual thoughts and desire for sexual activity that cannot be accounted for by another medical, physical, or psychiatric condition, or medication.  An estimated 1 in 10 women may have HSDD at some point in their life, for which therapies like flibanserin with a 9%- 13% responder rate over placebo, and S1 Biopharma's first in class, next-generation drug Lorexys have been developed to address.

S1 Biopharma is currently preparing for upcoming Phase IIb studies for Lorexys for the treatment of HSDD.  In its recently completed Phase IIa study, Lorexys demonstrated a 76% responder rate that was 38% greater than control.

About S1 Biopharma

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's pipeline of therapies is non-hormonal, acting on the sexual centers of the brain by restoring the natural balance of key neurotransmitters. S1 Biopharma's pipeline utilizes its trademark philosophy of identifying and combining mechanistically opposing agents that work synergistically to maximize beneficial effects on sexual function while minimizing side effects. The company's lead compound, Lorexys, recently completed a Phase IIa clinical trial for the treatment of hypoactive sexual desire disorder (HSDD).

For more information please visit www.s1biopharma.com.

Contact:
Nick Sitchon
nsitchon@s1biopharma.com
212-895-8915


'/>"/>
SOURCE S1 Biopharma
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuratus Lab Services Expands Capabilities with Acquisition of CMC Operation of Array BioPharma
2. EMD Millipore Introduces Compaction Technology to Improve Solubility and Facilitate Handling of Cell Culture Media Used in Biopharmaceutical Production
3. Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting
4. PDL BioPharma to Present at Jefferies 2015 Global Healthcare Conference
5. Array BioPharma To Present At The Jefferies 2015 Global Healthcare Conference
6. Technical Coverage on Biotech Stocks -- Anthera Pharma, RXi Pharma, MiMedx, Sarepta Therapeutics, and Navidea Biopharma
7. Intarcia Named To "CNBC Disruptor 50" List: One Of Only Two Biopharma Companies Named
8. DS Biopharma to Present at UBS Global Healthcare Conference
9. WeissLaw LLP Investigates the Synageva Biopharma Corp. Acquisition
10. CTI BioPharma Reports First Quarter 2015 Financial Results
11. PDL BioPharma Announces First Quarter 2015 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):